WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H562940
CAS#: 6266-54-2
Description: SM27 is an inhibitor of Fibroblast Growth Factor 2 (FGF2).
Hodoodo Cat#: H562940
Name: SM27
CAS#: 6266-54-2
Chemical Formula: C21H16N2O9S2
Exact Mass: 504.03
Molecular Weight: 504.480
Elemental Analysis: C, 50.00; H, 3.20; N, 5.55; O, 28.54; S, 12.71
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: SM27; SM-27; SM 27; NSC-37204; NSC 37204; NSC37204;
IUPAC/Chemical Name: 4-Hydroxy-6-((((8-hydroxy-6-sulfo-2-naphthyl)amino)carbonyl)amino)-2-naphthalenesulfonic acid
InChi Key: XUMPVMRAPYSHRQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H16N2O9S2/c24-19-9-15(33(27,28)29)5-11-1-3-13(7-17(11)19)22-21(26)23-14-4-2-12-6-16(34(30,31)32)10-20(25)18(12)8-14/h1-10,24-25H,(H2,22,23,26)(H,27,28,29)(H,30,31,32)
SMILES Code: O=S(C1=CC(O)=C2C=C(NC(NC3=CC=C4C=C(S(=O)(O)=O)C=C(O)C4=C3)=O)C=CC2=C1)(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 504.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Pinessi D, Foglieni C, Bugatti A, Moroni E, Resovi A, Ribatti D, Rusnati M, Giavazzi R, Colombo G, Taraboletti G. PO-15 - Antiangiogenic small molecule ligands of FGF2 derived from the endogenous inhibitor thrombospondin-1. Thromb Res. 2016 Apr;140 Suppl 1:S182. doi: 10.1016/S0049-3848(16)30148-7. Epub 2016 Apr 8. PubMed PMID: 27161705.
2: Foglieni C, Pagano K, Lessi M, Bugatti A, Moroni E, Pinessi D, Resovi A, Ribatti D, Bertini S, Ragona L, Bellina F, Rusnati M, Colombo G, Taraboletti G. Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors. Sci Rep. 2016 Mar 22;6:23432. doi: 10.1038/srep23432. PubMed PMID: 27000667; PubMed Central PMCID: PMC4802308.
3: Meli M, Pagano K, Ragona L, Colombo G. Investigating the dynamic aspects of drug-protein recognition through a combination of MD and NMR analyses: implications for the development of protein-protein interaction inhibitors. PLoS One. 2014 May 27;9(5):e97153. doi: 10.1371/journal.pone.0097153. eCollection 2014. PubMed PMID: 24865844; PubMed Central PMCID: PMC4035249.
4: Pagano K, Torella R, Foglieni C, Bugatti A, Tomaselli S, Zetta L, Presta M, Rusnati M, Taraboletti G, Colombo G, Ragona L. Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule. PLoS One. 2012;7(5):e36990. doi: 10.1371/journal.pone.0036990. Epub 2012 May 14. PubMed PMID: 22606323; PubMed Central PMCID: PMC3351436.
